Search for a trial

Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum-based Chemotherapy (TROPION-Lung05)

This study has been transitioned to CTIS with ID 2024-511449-21-00 check the CTIS register for the current data. Primary:To assess the efficacy of DS-1062a, as measured by the ORR, as a treatment for subjects with NSCLC with actionable genomic…

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS >=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)

This study has been transitioned to CTIS with ID 2023-507933-12-00 check the CTIS register for the current data. MAIN OBJECTIVES:- To compare the efficacy of Dato-DXd in combination with pembrolizumab versus pembrolizumab alone, as measured by…